|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,225.00 JPY | +1.22% |
|
+0.91% | -0.22% |
| 01-12 | Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026 | CI |
| 11-25 | US FDA approves Otsuka's drug for a type of kidney disease | RE |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
| 12 | ||||||||
| 16 | ||||||||
| 9 | ||||||||
| 18 | ||||||||
| 8 | ||||||||
| 12 | ||||||||
| - | 1 | |||||||
| 4 | ||||||||
| - | - | |||||||
| - | - | |||||||
| 2 | ||||||||
| - | - | - | - | |||||
| - | - | - | 2 | |||||
| 3 | ||||||||
| Average | 8 | |||||||
| Weighted average by Cap. | 12 |
- Stock Market
- Equities
- 4768 Stock
- Sector Otsuka Corporation
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















